Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 130 for your search:

Drug:  lenalidomide
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

An Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-016, NCT00179647

Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI 07-134, NCT00777881

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-000649-36, QUIREDEX, NCT00480363

Phase III Randomized Study of Consolidation Therapy Comprising Bortezomib and Dexamethasone With Versus Without Lenalidomide in Patients With Symptomatic Multiple Myeloma Who Have Completed a Dexamethasone-Based Induction Regimen

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1A05, E1A05, NCT00522392

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: SHEBA-07-4918-IH-CTIL, NCT00551928

Phase III Randomized Study of Melphalan, Prednisone, and Thalidomide Versus Melphalan, Prednisone, and Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1A06, E1A06, NCT00602641

Phase III Randomized Study of Lenalidomide and Low-Dose Dexamethasone With Versus Without Bortezomib in Patients With Previously Untreated Multiple Myeloma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0777, S0777, NCT00644228

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-020, NCT00689936

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-002, NCT00774345

10.

Phase III Randomized Study of Lenalidomide With Versus Without Epoetin Alfa in Patients With Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Symptomatic Anemia

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2905, E2905, NCT00843882

11.

Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: LenaMain-Trial, NCT00891384

12.

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and ovr
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-008, Eudract #: 2008-003079-32, NCT00910910

13.

A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Subjects With Previously Treated Mutiple Myeloma

Phase: Phase III
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-022, NCT00928486

14.

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-PC-002, EudraCT Number 2008-007969-23, NCT00988208

15.

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-150, NCT00378105

16.

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0461, NCT00294632

17.

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI LYM 58, NCT00633594

18.

Phase I/II Study of Chemoimmunotherapy Comprising Lenalidomide in Combination With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone in Patients With Newly Diagnosed Stage II-IV Diffuse Large Cell or Grade 3 Follicular B-Cell Lymphoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MAYO-MC078E, MC078E, CELGENE-RV-NHL-PI-0325, NCT00670358

19.

Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0712003357, NCT00698776

20.

Phase I/II Pilot Study of Lenalidomide, Fludarabine, and Cyclophosphamide in Patients With Advanced Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GIMEMA-LLC0606, GIMEMA-LLC0606, EUDRACT-2006-006185-42, EU-20865, NCT00727415

21.

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2007.098, NCT00724568

22.

Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CLL-5, EudraCT Nr. 2008-001430-27, ML21718, NCT00738829

23.

Phase I/II Study of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma and Renal Dysfunction

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MAYO-MC0885, MC0885, MAYO-08-003156, CELGENE-RV-MM-PI-0394, NCT00790842

24.

Dose-Finding of Lenalidomide as Maintenance in Multiple Myeloma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: Revlimid as maintenance in MM, NCT00778752

25.

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RV-MDS-PI-244, IND #101536, NCT00699842

Select All on Page

Help with Results

A Service of the National Cancer Institute